Mitsubishi Chemical Safety Institute

Mediford Corporation is a leading Japanese contract research organization (CRO) providing comprehensive drug development support services, including non-clinical safety assessment, bioanalysis, and central laboratory services. Established in November 2023 through the merger of LSIM Safety Institute and the drug development divisions of LSI Medience, the company operates as a subsidiary of PHC Holdings Corporation. Mediford traces its origins back to the Mitsubishi Chemical Safety Institute, founded in 1977, and maintains a strong reputation for GLP-compliant toxicology and pharmacology studies. With major facilities in Tokyo, Kashima, and Kumamoto, the company supports pharmaceutical and biotechnology clients globally in advancing candidates from discovery through clinical trials. Its expertise spans a wide range of modalities, including small molecules, biologics, and advanced therapies like cell and gene products.